Peterson LR. A review of tigecycline – the first glycylcycline. „International journal of antimicrobial agents”, s. S215–22, grudzień 2008. DOI: 10.1016/S0924-8579(09)70005-6. PMID: 19134522.
Malli E., Spiliopoulou I., Kolonitsiou F., Neocleous Ch., Klapsa D., Pantelidi K., Panopoulou M., Grapsa S., Alepopoulou E., Neonakis I., Alexiou-Daniel S., Bakola D., Koutsia-Carouzou C., Malamou-Lada H., Zerva L., Vlahaki E., Kartali-Ktenidou S., Anastassiou E., Petinaki E. In vitro activity of tigecycline against gram-positive cocci: a multicentre study in Greece. „The Journal of antimicrobial chemotherapy”. 5 (62), s. 1158–1160, listopad 2008. DOI: 10.1093/jac/dkn344. PMID: 18753190.
Bouchillon SK., Iredell JR., Barkham T., Lee K., Dowzicky MJ. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). „International journal of antimicrobial agents”. 2 (33), s. 130–136, luty 2009. DOI: 10.1016/j.ijantimicag.2008.07.031. PMID: 18995992.
Johnson MD., Decker CF. Antimicrobial agents in treatment of MRSA infections. „Disease-a-month: DM”. 12 (54), s. 793–800, grudzień 2008. DOI: 10.1016/j.disamonth.2008.09.002. PMID: 18996282.
Gales AC., Sader HS., Fritsche TR. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. „Diagnostic microbiology and infectious disease”. 4 (60), s. 421–427, kwiecień 2008. DOI: 10.1016/j.diagmicrobio.2007.10.017. PMID: 18068934.
Reid GE., Grim SA., Aldeza CA., Janda WM., Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. „Pharmacotherapy”. 8 (27), s. 1198–1201, sierpień 2007. DOI: 10.1592/phco.27.8.1198. PMID: 17655518.
MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. „The Journal of antimicrobial chemotherapy”, s. i11–6, wrzesień 2008. DOI: 10.1093/jac/dkn242. PMID: 18684702.
Zimmerman JJ., Raible DG., Harper DM., Matschke K., Speth JL. Evaluation of a potential tigecycline-warfarin drug interaction. „Pharmacotherapy”. 7 (28), s. 895–905, lipiec 2008. DOI: 10.1592/phco.28.7.895. PMID: 18576904.
nih.gov
ncbi.nlm.nih.gov
Peterson LR. A review of tigecycline – the first glycylcycline. „International journal of antimicrobial agents”, s. S215–22, grudzień 2008. DOI: 10.1016/S0924-8579(09)70005-6. PMID: 19134522.
Rossi F., Andreazzi D. Overview of tigecycline and its role in the era of antibiotic resistance. „The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases”. 3 (10), s. 203–216, czerwiec 2006. PMID: 17568854.
Backx M., Healy B. Serious staphylococcal infections. „Clinical medicine (London, England)”. 5 (8), s. 535–538, październik 2008. PMID: 18975490.
Malli E., Spiliopoulou I., Kolonitsiou F., Neocleous Ch., Klapsa D., Pantelidi K., Panopoulou M., Grapsa S., Alepopoulou E., Neonakis I., Alexiou-Daniel S., Bakola D., Koutsia-Carouzou C., Malamou-Lada H., Zerva L., Vlahaki E., Kartali-Ktenidou S., Anastassiou E., Petinaki E. In vitro activity of tigecycline against gram-positive cocci: a multicentre study in Greece. „The Journal of antimicrobial chemotherapy”. 5 (62), s. 1158–1160, listopad 2008. DOI: 10.1093/jac/dkn344. PMID: 18753190.
Bouchillon SK., Iredell JR., Barkham T., Lee K., Dowzicky MJ. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). „International journal of antimicrobial agents”. 2 (33), s. 130–136, luty 2009. DOI: 10.1016/j.ijantimicag.2008.07.031. PMID: 18995992.
Johnson MD., Decker CF. Antimicrobial agents in treatment of MRSA infections. „Disease-a-month: DM”. 12 (54), s. 793–800, grudzień 2008. DOI: 10.1016/j.disamonth.2008.09.002. PMID: 18996282.
Gales AC., Sader HS., Fritsche TR. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. „Diagnostic microbiology and infectious disease”. 4 (60), s. 421–427, kwiecień 2008. DOI: 10.1016/j.diagmicrobio.2007.10.017. PMID: 18068934.
Reid GE., Grim SA., Aldeza CA., Janda WM., Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. „Pharmacotherapy”. 8 (27), s. 1198–1201, sierpień 2007. DOI: 10.1592/phco.27.8.1198. PMID: 17655518.
MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. „The Journal of antimicrobial chemotherapy”, s. i11–6, wrzesień 2008. DOI: 10.1093/jac/dkn242. PMID: 18684702.
Esposito S., Noviello S., Leone S. [Skin and soft tissue infections: current therapeutic options]. „Le infezioni in medicina: rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive”. 2 (16), s. 65–73, czerwiec 2008. PMID: 18622145.
Gilson M., Moachon L., Jeanne L., Dumaine V., Eyrolle L., Morand P., Ben m’Rad M., Salmon D. Acute pancreatitis related to tigecycline: case report and review of the literature. „Scandinavian journal of infectious diseases”. 8 (40), s. 681–683, 2008. PMID: 18979610.
Zimmerman JJ., Raible DG., Harper DM., Matschke K., Speth JL. Evaluation of a potential tigecycline-warfarin drug interaction. „Pharmacotherapy”. 7 (28), s. 895–905, lipiec 2008. DOI: 10.1592/phco.28.7.895. PMID: 18576904.
Falagas ME., Karageorgopoulos DE., Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. „Current drug metabolism”. 1 (10), s. 13–21, styczeń 2009. PMID: 19149509.
